Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The study showed significant reductions in cardiovascular and heart failure hospitalizations, supporting acoramidis as a potentially more effective treatment option. These findings replicate earlier research and highlight the importance of reducing hospitalizations to improve patient outcomes. Further long-term studies are planned to confirm these benefits.
The study on Acoramidis versus Tafamidis in ATTR-CM provides context for health sector activity. As of Oct 11, 2026 23:11 WIB, 109 of 128 priced US health-sector stocks on Pluang rose while 18 fell. Notable movers include IOVA at USD 14.62 with a 9.84% increase, DFTX at USD 36.90 up 7.96%, and IBRX at USD 10.51 gaining 6.05%.
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
Solana's stablecoin reserves fell from $17.45 billion on September 25 to $16.33 billion by October 11, a 6.4% decline indicating that $1.12 billion left the chain. This reduction reflects actual sell or transfer activity, not price changes, and sugge...
Strategy announced it repurchased $176 million of its STRC preferred stock while acquiring 334 BTC in Q3 2026, reporting a $21 billion gain on digital assets. Michael Saylor confirmed that Bitcoin purchases will continue, framing the STRC buyback as ...
